Navigation Links
Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection
Date:12/10/2009

significantly higher than with placebo. RISPERDAL® CONSTA® is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS): NMS, a potentially fatal symptom complex, has been reported with the use of antipsychotic medications, including RISPERDAL® CONSTA®. Clinical manifestations include muscle rigidity, fever, altered mental status and evidence of autonomic instability (see full Prescribing Information). Management should include immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, intensive symptomatic treatment and medical monitoring, and treatment of any concomitant serious medical problems.

Tardive Dyskinesia (TD): TD is a syndrome of potentially irreversible, involuntary, dyskinetic movements that may develop in patients treated with antipsychotic medications. The risk of developing TD and the likelihood that dyskinetic movements will become irreversible are believed to increase with duration of treatment and total cumulative dose. Elderly patients appeared to be at increased risk for TD. Prescribing should be consistent with the need to minimize the risk of TD. The syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.

Hyperglycemia and Diabetes: Hyperglycemia, some cases extreme and associated with ketoacidosis, hyperosmolar coma or death has been reported in patients treated with atypical antipsychotics (APS), including RISPERDAL® CONSTA®. Patients starting treatment with APS who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing.

Hyperprolactinemia: As with other drugs that antagonize dopamine D2 receptors,

RISPERDAL® CONSTA® elevates prolactin levels and the elevation
'/>"/>

SOURCE Janssen(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 An experimental drug designed to help ... first treatment for anemia of inflammation, according to results from ... online today in Blood , the Journal ... Anemia is a condition that occurs when red ... properly. When an individual has anemia, the body does not ...
(Date:8/27/2014)... , Aug. 27, 2014  CVS Caremark (NYSE: ... a new clinical affiliation with MedStar Health, a leading ... Maryland and the Washington, DC ... affordable health care services for patients. Through this clinical ... to clinical support, medication counseling, chronic disease monitoring and ...
(Date:8/27/2014)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), ... for its third quarter of fiscal 2014: For ... Revenue of $1,291,378, a 13% decrease over the same period ... quarter of $240,156 compared to net income of $238,826 during ... For the nine months ended June 30, 2014: ...
Breaking Medicine Technology:Drug Represents First Potential Treatment for Common Anemia 2Drug Represents First Potential Treatment for Common Anemia 3CVS Caremark Announces New Clinical Affiliation with MedStar Health 2CVS Caremark Announces New Clinical Affiliation with MedStar Health 3Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3
... Calif., Oct. 1 Accuray Incorporated (Nasdaq: ARAY ... announced today publication of results from a study of ... The study demonstrated that erectile function was preserved in ... two years. Published rates of erectile function preservation at ...
... Systems, a Hill-Rom company, (NYSE: HRC ), announces ... with top orthopaedic surgeons. Carlos A. Guanche, M.D., managing ... surgeon and is recognized for his contributions in expanding ... elbow fractures, scopes and clavicle repair procedures. , ...
Cached Medicine Technology:Prostate Cancer Study Results Published on Patients Treated With CyberKnife Radiosurgery 2Prostate Cancer Study Results Published on Patients Treated With CyberKnife Radiosurgery 3Prostate Cancer Study Results Published on Patients Treated With CyberKnife Radiosurgery 4Allen Medical Systems Announces Surgeon Spotlight Series Interview 2Allen Medical Systems Announces Surgeon Spotlight Series Interview 3
(Date:8/27/2014)... (PRWEB) August 27, 2014 For nearly ... performances by the beloved mantra singers Deva Premal & ... Following the release of their latest album in May, ... down in twenty-two countries around the globe, including Russia, ... Argentina and across Europe. With a new album and ...
(Date:8/27/2014)... BESLER Consulting , a leading provider ... is pleased to announce that it has been named ... Companies. The list represents the most comprehensive look at ... , "It's been an exciting year for our company ... year's Inc. 5000 list,” said Jonathan Besler, BESLER’s President ...
(Date:8/27/2014)... August 27, 2014 Home Care ... care for seniors, is proud to announce the next ... upcoming webinar will feature Dr. Suzanne Steinbaum, attending cardiologist ... Hospital in New York City, National Spokesperson for the ... webinar will cover the issues surrounding women and heart ...
(Date:8/27/2014)... clinical trial participation in the largest ongoing observational study ... not representative of the larger patient base, according to ... Jay Udell. The study authors call into question the ... and suggest the use of broader enrollment criteria and ... know that clinical trials can be tremendously expensive and ...
(Date:8/27/2014)... (Lebanon, NH 8/27/14)Dartmouth cancer researchers developed and tested ... and environmental interactions that contribute to disease as ... , The approach fills a gap in ... from complex interactions among genetic and environmental factors. ... relevant interactions versus those that reflect chance combinations ...
Breaking Medicine News(10 mins):Health News:Deva Premal & Miten's Mantras For Life Tour Announced 2Health News:Deva Premal & Miten's Mantras For Life Tour Announced 3Health News:BESLER Consulting Among America’s Fastest Growing Private Companies 2Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:Participants of cardiac clinic trials do not represent real world patients, study finds 2Health News:Dartmouth isolates environmental influences in genome-wide association studies 2
... study, there is a connection between certain bacteria in ... of using probiotics to treat autism.// ... this study. Though the results are very preliminary, he ... propose any link between autism and childhood vaccinations. ...
... of medical tourism has created new vistas, enabling a ... world.// In the race for being the best in ... the industry’s powerful trident - Pharmaceutical Industry, Doctors and ... well as diseases”, said Karl Marx, and what better ...
... from Spain are not too comfortable with the outcome of ... grace//, could carry a risk of formation of fatal blood ... 2000 as an upgraded version of bare-metal stents. ... have the drug-lined versions of the stents, which are designed ...
... Attention Deficit Hyperactivity Disorder (ADHD) cannot sit calmly at ... health professionals and parents are familiar with the symptoms, ... topic. ,The FDA has given instructions that ... should put up warnings about the possible side effects ...
... James, the British chairman of the International Obesity Task ... the obesity epidemic in poor countries. ,"The ... which subsidize and distort the market to make fats ... James said at the 10th International Obesity Congress in ...
... 150th anniversary celebrations of Madras University, his alma mater ... institutions in India. ,Speaking on the occasion, ... "Good teaching emanates from research. Any university is judged ... academics here. ,He opened a virtual university ...
Cached Medicine News:Health News:Probiotics – a probable treatment for Autis 2Health News:Chemistry Over The Counter: Is It Just What The Doctor Ordered? 2Health News:Chemistry Over The Counter: Is It Just What The Doctor Ordered? 3Health News:Chemistry Over The Counter: Is It Just What The Doctor Ordered? 4Health News:Alternative therapies for ADHD 2Health News:Alternative therapies for ADHD 3Health News:President Launches Madras University's 150th Year Celebrations 2
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches....
12 mm diameter pigtail curved probes with eyes 4mm back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.9 inches....
The Novus 2000 argon laser combines power, size, and versatility. Ideal for the office, clinic and operating room environments, Novus 2000 is the world's most widely accepted ophthalmic laser....
The VISULAS 532s combines ease of use, efficiency and safety to provide ophthalmologists with an overall system sharply focused on their requirements. ,The VISULAS 532s is a laser of many talent...
Medicine Products: